Patents by Inventor Michael R. Knowles

Michael R. Knowles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of MTAP inhibitors for the treatment of lung disease
    Patent number: 10918641
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 16, 2021
    Assignees: The University of North Carolina at Chapel Hill, Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Charles R. Esther, Jr., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon
  • Use of MTAP Inhibitors for the Treatment of Lung Disease
    Publication number: 20180353511
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Application
    Filed: April 3, 2018
    Publication date: December 13, 2018
    Inventors: Charles R. Esther, JR., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon
  • METHODS AND COMPOSITIONS FOR DETECTING GENETIC MARKERS ASSOCIATED WITH PRIMARY CILIARY DYSKINESIA
    Publication number: 20100292088
    Abstract: The present invention provides methods and compositions for detecting mutations in a DNAH11 gene of a subject to diagnose primary ciliary dyskinesia (PCD) in the subject and/or to identify a subject as having an increased risk of having PCD and/or to identify a carrier of a PCD mutation.
    Type: Application
    Filed: May 14, 2010
    Publication date: November 18, 2010
    Inventors: Maimoona Banoo Abdul Hamid Zariwala, Michael R. Knowles
  • Method of administering amiloride
    Patent number: 5725842
    Abstract: Methods are disclosed for removing retained mucus secretions from the lungs of a human subject. The method includes (1) generating an aerosol suspension of respirable solid, dry particulate amiloride, and (2) delivering by inhalation the aerosol suspension to the respiratory system of the subject. The solid particulate amiloride is comprised of particles of about 1 to 5 microns and is free of liquid amiloride particles. The aerosol suspension of respirable solid particulate amiloride is administered in an amount sufficient to achieve concentrations of amiloride on the airway surfaces of from about 10.sup.-7 to 10.sup.-3 Moles/liter. As a result of the treatment, the secretions are hydrated and more easily transported from the lung via mucociliary action. Methods are also disclosed for the treatment of cystic fibrosis in humans.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: March 10, 1998
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Richard C. Boucher, Jr., Michael R. Knowles
  • Aerosolized amiloride treatment of retained pulmonary secretions
    Patent number: 4501729
    Abstract: This disclosure describes a method of treatment of retained pulmonary secretions by the use of aerosolized suspension of amiloride.
    Type: Grant
    Filed: December 13, 1982
    Date of Patent: February 26, 1985
    Assignee: Research Corporation
    Inventors: Richard C. Boucher, John T. Gatzy, Michael R. Knowles